Volume 41, Issue 1 e70011
CLINICAL REVIEW
Open Access

Catheter ablation using pulsed-field energy: Advantages and limitations compared with conventional energy

Kenji Kuroki MD, PhD

Kenji Kuroki MD, PhD

Department of Cardiology, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan

Search for more papers by this author
Hiroshi Tada MD, PhD

Corresponding Author

Hiroshi Tada MD, PhD

Department of Cardiovascular Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan

Correspondence

Hiroshi Tada, Department of Cardiovascular Medicine, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuokashimoaizuki, Eiheiji, Yoshida District, Fukui 910-1193, Japan.

Email: [email protected]

Search for more papers by this author
First published: 04 February 2025
Citations: 3

Abstract

Atrial fibrillation (AF) poses significant risks of heart failure and stroke, emphasizing effective treatment. Catheter ablation using thermal energy sources, such as radiofrequency or cryoballoon ablation, has shown greater success in maintaining sinus rhythm compared with drug therapy. However, thermal ablation (TA) is associated with serious complications, such as atrial-esophageal fistula, phrenic nerve palsy, and pulmonary vein stenosis. Pulsed-field ablation (PFA) is an emerging ablation energy source that uses electroporation to selectively target cardiac tissue while sparing adjacent structures such as nerves and blood vessels. Two randomized controlled trials have demonstrated that PFA is comparable to TA in both efficacy and safety at a 1-year follow-up and had shorter procedure times. A review of six meta-analyses consistently showed shorter procedural times for PFA across all studies. Additionally, three out of the four recent studies with large samples reported lower recurrence rates with PFA. Regarding complication rates, four out of four studies showed lower incidences of phrenic nerve injury with PFA, and two out of three studies reported lower rates of esophageal injury with PFA. However, four out of four studies indicated higher incidences of cardiac tamponade with PFA, highlighting the need for caution among early-career operators. Furthermore, careful monitoring is required considering the possible unforeseen complications specific to PFA and the lack of long-term follow-up data. Despite these concerns, PFA shows promise as a safer, more effective, and efficient alternative to TA for AF, particularly as operator experience and device technology continue to advance.

CONFLICT OF INTEREST STATEMENT

Dr. Kenji Kuroki received grants from Medtronic Co., Ltd. and Abbott Medical Japan LLC. Dr. Kuroki is a consultant for Abbott Medical Japan LLC, Microport CRM Japan Co., Ltd., and Kaneka Corporation. Dr. Hiroshi Tada received honoraria for lectures or speakers bureaus from Daiichi Sankyo Company, Ltd., Novartis Pharma K.K., Medtronic Japan Co., Ltd., Biotronik Japan, Inc., Bristol Myers Squibb, and Boston-Scientific Japan K.K. Dr. Tada also received grants (Investigator-initiated study unrelated to the manuscript topic) from Abbott Medical Japan LLC, Daiichi Sankyo Company, Ltd., Nippon Boehringer Ingelheim Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., and Marubun Tsusyo K.K.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.